Compare Organon & Co. Common Stock (OGN) vs Valley National Bancorp Common Stock (VLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Valley National Bancorp Common Stock — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Valley National Bancorp Common Stock trades at $12.39 (market cap $6.92B). The key difference: Valley National Bancorp Common Stock is the larger of the two by market cap, and Valley National Bancorp Common Stock pays the higher dividend (3.51%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Valley National Bancorp Common Stock for 6 Days on average.
| OGN | VLY | |
|---|---|---|
Market Cap | $3.62B | $6.92B |
Volume | 2,892,999 | 6,202,090 |
Sector | Health | Financials |
52-Week High | $13.81 | $15.19 |
52-Week Low | $5.70 | $9.72 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $11.04B | $9.43B |
Dividend Yield | 0.58% | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Valley National Bancorp (VLY) trades at $12.53, down 0.87% with a bearish technical outlook. The stock shows strong fundamentals with a P/E of 10.61 and P/B of 0.91, indicating potential undervaluation. Recent earnings show mixed results with Q2 2026 missing estimates, but revenue growth remains solid at $2.2B for 2026. The company is actively expanding through acquisitions including Bluevine and Providence Financial to strengthen its deposit base and Chicago market presence.
Analyst consensus remains bullish with 62% buy ratings and a $16.50 price target, suggesting 32% upside potential. Key risks include integration challenges from recent acquisitions and higher operating expenses impacting margins. The upcoming Q3 2026 earnings report on October 22 will be crucial for validating growth trajectory amid current bearish technical signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Valley National Bancorp Common Stock
Valley National Bancorp is a financial holding company whose main subsidiary is Valley National Bank. It provides commercial, retail, trust, and investment services across several U.S. states.
Read more on VLY →
